Commercial Insight: Antihormonal Cancer Therapies - Stagnant sales indicative of a mature market

Table of Contents

EXECUTIVE SUMMARY

• Strategic scoping and focus
• Datamonitor insight into the antihormonal cancer therapies market
• Related reports
• Upcoming related reports

MARKET DEFINITION

• Definition of the cancer market
• Antihormonal therapies by ATC class
  • L2A3 - Luteinizing hormone-releasing hormone agonists
  • L2B1 - Anti-estrogens
  • L2B2 - Anti-androgens
  • L2B3 - Aromatase inhibitors
  • L2B9 - Other hormone antagonists

MARKET OVERVIEW

• Seven major markets
  • Current and future market overview
  • Opportunities and threats

• US
  • Current and future market assessment
  • Opportunities and threats

• Japan
  • Current and future market assessment
  • Opportunities and threats

• Five major European markets (5EU)
  • Current and future market assessment
  • Opportunities and threats

• France
  • Current and future market assessment

• Germany
  • Current and future market assessment

• Italy
  • Current and future market assessment

• Spain
  • Current and future market assessment

• UK
  • Current and future market assessment

• Rest of the world snapshot
  • Current market assessment
  • Opportunities and threats

BRAND DYNAMICS

• Overview of competitive landscape
  • Arimidex, Lupron and Casodex will remain the top 3 antihormonal brands in 10 years' time

• Drivers of brand choice
  • Efficacy and toxicity are the most important drivers of brand choice

• Trends in marketing strategies
  • Marketing strategy for leading brands
  • Patient information and support programs
  • Direct-to-Consumer advertising

• Arimidex (anastrozole; AstraZeneca)
  • Drug profile
  • Product positioning
  • SWOT analysis
  • Brand forecast to 2018

• Lupron (leuprolide; Takeda/Abbott)
  • Drug profile
  • Product positioning
  • SWOT analysis
  • Brand forecast to 2018

• Casodex (bicalutamide; AstraZeneca)
  • Drug profile
  • Product positioning
  • SWOT analysis
  • Brand forecast to 2018

KEY DEVELOPERSSTRATEGIC OVERVIEW

• Trends in corporate strategy
  • Strategic lifecycle management is essential in the antihormonals market
  • Commercialization partnerships are common for smaller players

• AstraZeneca
  • Corporate strategy
  • Oncology antihormonals portfolio assessment

• Takeda
  • Corporate strategy
  • Oncology antihormonals portfolio assessment

• Portfolio assessment of other leading companies

CASE STUDY

• Portfolio management: the example of AstraZeneca
  • A first-to-market status is a good start...
  • ...but strategic portfolio management is essential to maintain shareholder value

BIBLIOGRAPHY

• Datamonitor reports
• Other

APPENDIX A - MARKET ASSUMPTIONS

• New product launches
• Patent expiries
• Data definitions, limitations and assumptions
  • Standard units
  • Japanese market data
  • Rest of World
  • Derivation of sales forecasts and pricing trends

• Forecast methodology

APPENDIX B

TABLES

• Table: Definition of the cancer market, 2009
• Table: Sales and growth of antihormonal therapy drug classes in the seven major markets, 2008 - 2018
• Table: Key events impacting the antihormonal therapies market, 2008 - 2018
• Table: Antihormonal therapies sales forecasts in the seven major markets ($m), 2008 - 2018
• Table: Summary of opportunities and threats to impact the antihormonals market across the seven major markets, 2009
• Table: Sales and growth of antihormonal therapy drug classes in the US, 2008 - 2018
• Table: Top 5 branded antihormonals in the US in 2008 and 2018
• Table: Antihormonal therapy sales forecasts in the US ($m), 2008 - 2018
• Table: Summary of opportunities and threats to impact the antihormonal market in the US, 2009 - 2018
• Table: Sales and growth of antihormonal therapy drug classes in Japan, 2008 - 2018
• Table: Top 5 branded antihormonals in Japan in 2008 and 2018
• Table: Antihormonal therapy sales forecasts in Japan ($m), 2008 - 2018
• Table: Summary of opportunities and threats to impact the antihormonals market in Japan, 2009 - 2018
• Table: Sales and growth of antihormonal therapy drug classes in the five major European markets, 2008 - 2018
• Table: Top 5 branded antihormonals in the five major European markets in 2008 and 2018
• Table: Antihormonal therapy sales forecasts in the five major European markets ($m), 2008 - 2018
• Table: Summary of opportunities and threats to impact the antihormonals market in the five major European markets, 2009
• Table: Top 5 branded antihormonals in France in 2008 and 2018
• Table: Antihormonal therapy sales forecasts in France ($m), 2008 - 2018
• Table: Top 5 branded antihormonals in Germany in 2008 and 2018
• Table: Antihormonal therapy sales forecasts in Germany ($m), 2008 - 2018
• Table: Top 5 branded antihormonals in Italy in 2008 and 2018
• Table: Antihormonal therapy sales forecasts in Italy ($m), 2008 - 2018
• Table: Top 5 branded antihormonals in Spain in 2008 and 2018
• Table: Antihormonal therapy sales forecasts in Spain ($m), 2008 - 2018
• Table: Top 5 branded antihormonals in the UK in 2008 and 2018
• Table: Antihormonal therapy sales forecasts in the UK ($m), 2008 - 2018
• Table: Comparison of antihormonal drug class sales ($m) in the seven major markets and rest of the world, 2008
• Table: Leading branded antihormonal therapy drug sales in the seven major markets ($m), 2008-2018
• Table: Marketing strategies employed by companies behind the top 3 antihormonal brands, 2009
• Table: Arimidex (anastrozole) - drug profile, 2009
• Table: Impacting factors on the revenues of Arimidex, 2008 - 2018
• Table: Lupron (leuprolide) - drug profile, 2009
• Table: Impacting factors on the revenues of Lupron, 2008 - 2018
• Table: Casodex (bicalutamide) - drug profile, 2009
• Table: Impacting factors on the revenues of Casodex, 2008 - 2018
• Table: Leading companies in the antihormonals market in the seven major pharmaceutical markets, 2008 - 2018
• Table: Assessment of AstraZeneca' s cancer antihormonals portfolio, 2009
• Table: Assessment of Takeda' s cancer antihormonals portfolio, 2009
• Table: Assessment of Novartis' s cancer antihormonals portfolio, 2009
• Table: Assessment of Pfizer' s cancer antihormonals portfolio, 2009
• Table: Assessment of Sanofi-Aventis' s cancer antihormonals portfolio, 2009
• Table: Regional launch dates for new antihormonals in the seven major markets, 2008 - 2018
• Table: Patent expiry dates for the approved antihormonals in the seven major pharmaceutical markets, 2008 - 2018

FIGURES

• Figure: Comparison of brand versus generic value of antihormonal therapies in 2008 and 2018 in the seven major pharmaceutical markets
• Figure: Antihormonal therapy sales ($m) by country, 2008 - 2018
• Figure: Antihormonal therapy sales ($m) by drug class in the seven major markets, 2008 - 2018
• Figure: Performance of leading antihormonal therapy brands in the seven major markets, 2008 versus 2018
• Figure: Antihormonal therapy sales ($m) in the US, 2008 - 2018
• Figure: Antihormonal therapy sales ($m) in Japan, 2008 - 2018
• Figure: Antihormonal therapy sales ($m) in the five major European markets, 2008 - 2018
• Figure: Antihormonal therapy sales ($m) in France, 2008 - 2018
• Figure: Antihormonal therapy sales ($m) in Germany, 2008 - 2018
• Figure: Antihormonal therapy sales ($m) in Italy, 2008 - 2018
• Figure: Antihormonal therapy sales ($m) in Spain, 2008 - 2018
• Figure: Antihormonal therapy sales ($m) in the UK, 2008 - 2018
• Figure: Rest of the world versus seven major market sales split in the antihormonal therapies market ($m), 2008
• Figure: Drivers of brand choice for antihormonal cancer therapy, 2009
• Figure: Example of Arimidex patient information and support programs
• Figure: Femara free trial program
• Figure: Frequency of cancer-related DTC advertising, January 2003 - June 2006
• Figure: Arimidex SWOT analysis, 2009
• Figure: Arimidex forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Lupron SWOT analysis, 2009
• Figure: Lupron forecast sales ($m) by country in the seven major markets, 2008 - 2018
• Figure: Casodex SWOT analysis, 2009
• Figure: Casodex forecast sales ($m) by country in the seven major markets, 2008 - 2018